The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia (AML). In this interview, Richard Dillon, MBBS, from King’s College London, UK, discusses the importance of using MRD in these patients and how its use in the UK has advanced. Dr Dillion discusses the Phase III MyeChild01 (NCT02724163) and AML19 (ISRCTN78449203) trials for children and younger adults with AML. These studies are effectively utilizing MRD measurement as a key marker to choose which patients undergo transplantation. The studies are also collecting additional data, on factors such as quality of life, health economics and resource use, to see if MRD techniques can be used to improve the efficiency of treatment. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, Liverpool, UK.
Advancements in the use of MRD in AML in the UK: MyeChild01 and AML19
